This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Komura, E. Articles by Giraudier, S. Search for Related Content PubMed PubMed Citation Articles by Komura, E. Articles by Giraudier, S.

Role for the Nuclear Factor B Pathway in Transforming Growth Factor-ß1 Production in Idiopathic Myelofibrosis: Possible Relationship with FK506 Binding Protein 51 Overexpression

¹ Institut National de la Sante et de la Recherche Medicale U362, Institut Gustave Roussy, Villejuif, France; ² Laboratoire d'Hématologie, Hôpital Henri Mondor, Créteil, France; and ³ EMI0210, Tour Pasteur, Hôpital Necker-Enfants Malades, Paris, France

Requests for reprints: Stéphane Giraudier, Institut National de la Sante et de la Recherche Medicale U362, Pavillon de recherche 1, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France. Phone: 33-1-4211-5233; Fax: 33-1-4211-5240; E-mail: stephane.giraudier{at}hmn.ap-hop-paris.fr.

The release of transforming growth factor-ß1 (TGF-ß1) in the bone marrow microenvironment is one of the main mechanisms leading to myelofibrosis in murine models and probably in the human idiopathic myelofibrosis (IMF). The regulation of TGF-ß1 synthesis is poorly known but seems regulated by nuclear factor B (NF-B). We previously described the overexpression of an immunophilin, FK506 binding protein 51 (FKBP51), in IMF megakaryocytes. Gel shift and gene assays show that FKBP51's overexpression in a factor-dependent hematopoietic cell line, induces a sustained NF-B activation after cytokine deprivation. This activation correlates with a low level of IB. A spontaneous activation of NF-B was also detected in proliferating megakaryocytes and in circulating CD34⁺ patient cells. In normal cells, NF-B activation was only detected after cytokine treatment. The expression of an NF-B superrepressor in FKBP51 overexpressing cells and in derived megakaryocytes from CD34⁺ of IMF patients revealed that NF-B activation was not involved in the resistance to apoptosis after cytokine deprivation of these cells but in TGF-ß1 secretion. These results highlight the importance of NF-B's activation in the fibrosis development of this disease. They also suggest that FKBP51's overexpression in IMF cells could play an important role in the pathogenesis of this myeloproliferative disorder.

This article has been cited by other articles:

				T. L. Criswell, N. Dumont, J. V. Barnett, and C. L. Arteaga Knockdown of the Transforming Growth Factor-{beta} Type III Receptor Impairs Motility and Invasion of Metastatic Cancer Cells Cancer Res., September 15, 2008; 68(18): 7304 - 7312. [Abstract] [Full Text] [PDF]

				B. S. Wilkins, W. N. Erber, D. Bareford, G. Buck, K. Wheatley, C. L. East, B. Paul, C. N. Harrison, A. R. Green, and P. J. Campbell Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes Blood, January 1, 2008; 111(1): 60 - 70. [Abstract] [Full Text] [PDF]

				S. R. Kim, K. S. Lee, S. J. Park, K. H. Min, K. Y. Lee, Y. H. Choe, Y. R. Lee, J. S. Kim, S. J. Hong, and Y. C. Lee PTEN Down-Regulates IL-17 Expression in a Murine Model of Toluene Diisocyanate-Induced Airway Disease J. Immunol., November 15, 2007; 179(10): 6820 - 6829. [Abstract] [Full Text] [PDF]

				K. A. Duthie, L. C. Osborne, L. J. Foster, and N. Abraham Proteomics Analysis of Interleukin (IL)-7-induced Signaling Effectors Shows Selective Changes in IL-7R{alpha}449F Knock-in T Cell Progenitors Mol. Cell. Proteomics, October 1, 2007; 6(10): 1700 - 1710. [Abstract] [Full Text] [PDF]

				M. S. Cairo Myelofibrosis with myeloid metaplasia: targeted therapy Blood, July 1, 2007; 110(1): 2 - 3. [Full Text] [PDF]

				O. Wagner-Ballon, D. F. Pisani, T. Gastinne, M. Tulliez, R. Chaligne, C. Lacout, F. Aurade, J.-L. Villeval, P. Gonin, W. Vainchenker, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice Blood, July 1, 2007; 110(1): 345 - 353. [Abstract] [Full Text] [PDF]

				R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF]

				P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF]

				W. Qi, X. Chen, J. Holian, E. Mreich, S. Twigg, R. E. Gilbert, and C. A. Pollock Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells Am J Physiol Renal Physiol, November 1, 2006; 291(5): F1070 - F1077. [Abstract] [Full Text] [PDF]

				K. S. Lee, S. J. Park, S. R. Kim, K. H. Min, S. M. Jin, H. K. Lee, and Y. C. Lee Modulation of Airway Remodeling and Airway Inflammation by Peroxisome Proliferator-Activated Receptor {gamma} in a Murine Model of Toluene Diisocyanate-Induced Asthma J. Immunol., October 15, 2006; 177(8): 5248 - 5257. [Abstract] [Full Text] [PDF]

				O. Wagner-Ballon, H. Chagraoui, E. Prina, M. Tulliez, G. Milon, H. Raslova, J.-L. Villeval, W. Vainchenker, and S. Giraudier Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin. J. Immunol., June 1, 2006; 176(11): 6425 - 6433. [Abstract] [Full Text] [PDF]